𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunogenicity of a hepatitis A virus vaccine

✍ Scribed by Bertram Flehmig; Angelika Haage; Mechthild Pfisterer

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
555 KB
Volume
22
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Hepatitis A virus (HAV) strain HAV/HFS/GBM was adapted to and grown in human diploid fibroblast cells. The HAV was concentrated by ammonium sulphate precipitation and high-speed centrifugation. The virus was inactivated by beta-propiolacton and purified by sedimentation through a 20% solution of sucrose and by CsCl gradient centrifugation. The immunogenicity of different preparations was tested in mice, guinea pigs, and goats. The immune response after vaccination was tested by determination of anti-HAV with RIA and of neutralizing antibodies with an appropriate test system. Results showed that anti-HAV titers of 1:1,000 and greater, as well as neutralizing antibody titers of 1:1,000 and greater, were found in sera of animals vaccinated with different preparations. It became evident that good anti-HAV titers persisted over a period of at least 1.5 years in goats and mice after immunization with a semipurified HAV vaccine, and titers up to 1:200 were present in mice 2 years after vaccination with a highly purified HAV vaccine.

πŸ“œ SIMILAR VOLUMES

Immunogenicity and safety in adults of h
Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later
✍ H. Briem; A. Safary πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 288 KB

## Abstract An inactivated vaccine against hepatitis A was administered as a single 1,440 enzyme‐linked immunosorbent assay (ELISA) units dose at month 0 with a booster at month 6 to 200 subjects divided into two age groups: group 1, 20–39 years (n = 134) and group II, 40–62 years (n = 66). At day

Novel chitosan derivative nanoparticles
Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice
✍ Lei Jiang; Feng Qian; Xiaowen He; Fang Wang; Ding Ren; Ying He; Ka Li; Shuhan Su πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 752 KB

## Abstract ## Background Chitosan has been shown to possess useful properties such as non‐toxicity, high biocompatibility and non‐antigenicity that offer advantages for vaccine delivery systems. In this study, we prepared novel chitosan derivative nanoparticles as DNA vaccine carriers and the pot

Safety and immunogenicity of a recombina
Safety and immunogenicity of a recombinant hepatitis B vaccine
✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.

Immunogenicity of a five-microgram dose
Immunogenicity of a five-microgram dose of hepatitis B vaccine
✍ George Papaevangelou; Anastasia Roumeliotou-Karayannis; Charalambos Vissoulis; S πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 291 KB

The immunogenicity of a 5-micrograms dose of vaccine (H-B-Vax, MSD) was evaluated in 50 young adults (17-19 years). Results were compared to our previous studies using similarly prepared vaccines using 20 micrograms and 10 micrograms per dose with the same trial protocol in a comparable population.